Inquiry Basket
MC-VC-PABC is a potent and selective antibody-drug conjugate (ADC) used in the treatment of various cancers, including breast cancer, ovarian cancer, and non-small cell lung cancer. It combines the efficacy of a monoclonal antibody with the cytotoxicity of a potent chemotherapeutic agent, delivering targeted therapy directly to cancer cells while minimizing systemic side effects. MC-VC-PABC specifically targets cancer cells overexpressing certain antigens, making it a promising option for personalized cancer treatment.
| Catalog Number | Size | Price | Quantity | |
|---|---|---|---|---|
| BADC-01494 | -- | $-- | Inquiry |
MC-VC-PABC is a versatile peptide-drug conjugate (PDC) that is particularly useful in targeted cancer therapy. The conjugate features a cleavable valine-citrulline (VC) linker, which is sensitive to the enzymes overexpressed in tumor environments. This linker enables selective release of the cytotoxic drug, ensuring that the therapeutic agent is activated directly at the site of the tumor. By minimizing the exposure of healthy tissues to the drug, MC-VC-PABC significantly reduces systemic toxicity while maintaining high efficacy in killing cancer cells. This targeted approach enhances the overall therapeutic index of the drug.
Another significant application of MC-VC-PABC is in drug delivery optimization. The peptide component of the conjugate plays a key role in guiding the drug to specific cancer cells, while the VC linker ensures that the drug is only activated within the tumor. This targeted delivery system improves the pharmacokinetics of the drug by prolonging its circulation time and increasing its accumulation at the tumor site. The controlled release mechanism enhances the drug’s therapeutic efficacy and minimizes unwanted side effects, offering a more efficient alternative to conventional chemotherapy.
MC-VC-PABC also demonstrates promise in combination therapies. When combined with other chemotherapeutic agents or immune therapies, MC-VC-PABC can act synergistically to increase the overall treatment effectiveness. The targeted delivery of the cytotoxic agent, combined with the ability to work alongside immune-modulating drugs, can help overcome resistance mechanisms in tumors that are unresponsive to single-agent therapies. This makes MC-VC-PABC a valuable addition to multi-drug treatment regimens, which are often necessary for treating aggressive or refractory cancers.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
